Table 2.
Past and ongoing anti-EGFR rechallenge clinical trials.
| Trial | Phase | N° of patients | Treatment | Median N° prev lines | ORR (%) | mPFS months |
|---|---|---|---|---|---|---|
| Santini 2012 | II, retrospective | 39 | Irinotecan + cetuximab | 4 | 54 | 6.6 |
| CC 08 2016
(Tsuji) |
II, retrospective | 34 | Irinotecan + cetuximab/FOLFIRI + cetuximab | 3 | 1 | 2.4 |
| Tanioka 2018 | II, retrospective | 14 | Irinotecan + cetuximab | 5 | 21.4 | 4.4 |
| Cricket 2018
(Cremolini) |
II, prospective | 28 | Irinotecan + cetuximab | 3 | 21 | 4 |
| CAVE mCRC
(completed) |
II, prospective | 77 | Avelumab + cetuximab | >2 | - | - |
| VELO
(ongoing) |
II, prospective | 112 | TAS102+ panitumumab | 2 | - | - |
| FIRE 4
(ongoing) |
III, prospective | Irinotecan based therapy + cetuximab | 2 | - | - | |
| CHRONOS
(ongoing) |
III, prospective | Panitumumab | 2 | - | - | |
| A-REPEAT | II, prospective | FOLFIRI or FOLFOX + panitumumab | 2 | - | - | |
| REGAIN
(completed) |
II, prospective | Irinotecan + cetuximab | 2 | - | - | |
| NCT03524820 | II, prospective | Cetuximab or cetuxumab + chemotherapy | 2 | - | - | |
|
NCT03087071
Cohort 3 |
II, prospective | panitumumab | 2 | - | - |
EGFR, epidermal growth factor receptor; mCRC, metastatic colorectal cancer; mPFS, median progression free survival; ORR, overall response rate.